Research ExplorerScientific StaffThomas Haalck Publications

Thomas Haalck

graph of relations
Affiliations
1 - 7 out of 7Page size: 50

Publications

  1. 2023

  2. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma

    Geidel, G., Adam, L., Rünger, A., Menz, A., Kött, J., Haalck, T. & Gebhardt, C., 12.2023, In: J EUR ACAD DERMATOL. 37, 12, p. e1414-e1416

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  3. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors

    Stadler, J-C., Keller, L., Mess, C., Bauer, A. T., Koett, J., Geidel, G., Heidrich, I., Vidal-Y-Sy, S., Andreas, A., Stramaglia, C., Sementsov, M., Haberstroh, W., Deitert, B., Hoehne, I. L., Reschke, R., Haalck, T., Pantel, K., Gebhardt, C. & Schneider, S. W., 05.2023, In: J IMMUNOTHER CANCER. 11, 5, e006456.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. 2018

  5. Knockdown of L1CAM significantly reduces metastasis in a xenograft model of human melanoma: L1CAM is a potential target for anti-melanoma therapy

    Ernst, A-K., Putscher, A., Samatov, T. R., Suling, A., Galatenko, V. V., Shkurnikov, M. Y., Knyazev, E. N., Tonevitsky, A. G., Haalck, T., Lange, T., Maar, H., Schröder-Schwarz, J., Riecken, K., Schumacher, U. & Wicklein, D., 2018, In: PLOS ONE. 13, 2, p. e0192525

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  6. 2017

  7. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker

    Akyüz, N., Brandt, A., Stein, A., Schliffke, S., Mährle, T., Quidde, J., Goekkurt, E., Loges, S., Haalck, T., Ford, C., Asemissen, A. M., Thiele, B., Radloff, J., Thenhausen, T., Krohn-Grimberghe, A., Bokemeyer, C. & Binder, M., 01.06.2017, In: INT J CANCER. 140, 11, p. 2535-2544

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  8. 2016

  9. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy

    Kaehler, K. C., Blome, C., Forschner, A., Gutzmer, R., Haalck, T., Heinzerling, L., Kornek, T., Livingstone, E., Loquai, C., Maul, L. V., Lang, B. M., Schadendorf, D., Stade, B., Terheyden, P., Utikal, J., Wagner, T., Hauschild, A., Garbe, C. & Augustin, M., 11.2016, In: MEDICINE. 95, 46, p. e5375

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  10. 2014

  11. The microenvironment in the human lung partly determines the site of the first metastasis

    Yanar, M., Abel, F., Haalck, T., Klutmann, S. & Schumacher, U., 01.07.2014, In: ANTICANCER RES. 34, 7, p. 3845-9 5 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  12. 2013

  13. Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.

    Janjetovic, S., Bacher, U., Haalck, T., Janning, M., Bokemeyer, C. & Fiedler, W., 2013, In: ACTA HAEMATOL-BASEL. 129, 2, p. 121-125 5 p., 2.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review